PROM1 and Familial prostate cancer: A study suggested that 35/46 (76%) CTCs were CD133-positive, a putative prostate cancer stem cell marker, in 35 patients with high-risk, localized prostate cancer; the researchers demonstrated that the CD133 and E-cadherin-positive CTC fragments were associated with biochemical recurrence at 1 year [65].